We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Novel Pathology Could Improve Diagnosis and Treatment of Huntington’s Disease
News

Novel Pathology Could Improve Diagnosis and Treatment of Huntington’s Disease

Novel Pathology Could Improve Diagnosis and Treatment of Huntington’s Disease
News

Novel Pathology Could Improve Diagnosis and Treatment of Huntington’s Disease

Credit: Robina Weermeijer/Unsplash
Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Novel Pathology Could Improve Diagnosis and Treatment of Huntington’s Disease"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Bristol scientists have discovered a novel pathology that occurs in several human neurodegenerative diseases, including Huntington’s disease.

The article, published in Brain Pathology, describes how SAFB1 expression occurs in both spinocerebellar ataxias and Huntington's disease and may be a common marker of these conditions, which have a similar genetic background.

SAFB1 is an important protein controlling gene regulation in the brain and is similar in structure to other proteins associated with neurodegenerative diseases of age. The team, from the University of Bristol’s Translational Health Sciences, wanted to find out if this protein might be associated with certain neurodegenerative conditions.

The researchers analyzed SAFB1 expression in the post-mortem brain tissue of spinocerebellar ataxias (SCA’s), Huntington’s disease (HD), Multiple sclerosis (MS), Parkinson’s disease patients and controls.

They found that SAFB becomes abnormally expressed in the nerve cells of brain regions associated with SCA and HD. Both of these conditions are associated with a specific pathology, called a polyglutamine expansion (an amino acid repeat), which only occurs in SCAs  and HD. The same pathology was therefore not seen in control Parkinson's disease or multiple sclerosis.

“These novel findings highlight a previously unknown mechanism causing disease which, importantly, suggests SAFB1 may be a diagnostic marker for polyglutamine expansion diseases, such as HD said lead author, James Uney, Professor of Molecular Neuroscience at the University of Bristol.

“We were also able to demonstrate how SAFB1 binds the SCA1 gene with the disease causing polyglutamine expansion (which causes spinocerebellar ataxia 1). As well as identifying a possible diagnostic marker, these findings open up the possibility of developing new therapeutic treatments for these rare but devastating neurodegenerative diseases.

“The next step is to establish whether inhibiting SAFB1 expression protects patients.”

Professor Uney said there was scope in the future to broaden the study to include other diseases, such as Alzheimer's, disease.

Reference


Buckner et al. (2020). Abnormal scaffold attachment factor 1 expression and localisation in spinocerebellar ataxias and huntington’s chorea. Brain Pathology. DOI: https://doi.org/10.1111/bpa.12872 

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Advertisement